Navigation Links
Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
Date:9/19/2008

EAST NORRITON, Pa., Sept. 19 /PRNewswire/ -- Tengion Inc., a clinical stage regenerative medicine company focused on the development of neo-organs and neo-tissues, today announced that it was one of only three companies featured as models of venture capital-backed innovation and success at the 35th Anniversary Celebration of the National Venture Capital Association (NVCA). P. Sherrill Neff, Partner at Quaker BioVentures -- a venture capital investor in Tengion -- presented a Tengion case study at the event on Thursday, September 18, 2008 in Mountain View, California.

For this 35th Anniversary Celebration event, the NVCA invited Tengion to showcase its Autologous Organ Regeneration Platform(TM) for nearly 200 invitation-only guests, including leading venture capitalists and entrepreneurs. The presentation was followed by a panel discussion of how to best encourage technological advances and maintain a robust pipeline of venture capital-backed innovation over the next 35 years.

"We are pleased and honored that the National Venture Capital Association selected Tengion to present at this 35th Anniversary Celebration," said Steven Nichtberger, M.D., President and CEO of Tengion. "We would like to extend our thanks to Sherrill Neff and Brenda Gavin of Quaker BioVentures and all of our investors who have worked so closely with the company to support our growth and the advances of our neo-organ and neo-tissue programs. We look forward to continuing to innovate and, ultimately, bringing important medical advances to patients who need them."

The NVCA represents more than 470 venture capital firms in the United States. Founded in 1973, the NVCA's mission is to foster a greater understanding of the importance of venture capital to the U.S. economy, and support entrepreneurial activity and innovation. The organization has marked its 35th Anniversary with key news announcements and several events in 2008.

About Tengion

Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create a functional neo-organ or neo-tissue that is designed to catalyze the body's innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies.


'/>"/>
SOURCE Tengion Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
2. Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
3. Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
4. Tengion Appoints Jeff Randall to Board of Directors
5. Tengion to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
7. Preliminary Report of American Biotech Labs HIV Study Featured in Inaugural Issue of Journal of the Science of Healing Outcomes
8. Resverlogixs Lead Drug Featured in Key Scientific Publication
9. Radiesse(R) Dermal Filler Featured Prominently in Journal of Dermatologic Surgery Special Issue on Fillers
10. PTC124 Featured at Third Annual Congress of Myology
11. Boston Scientifics SpyGlass(R) Direct Visualization System to Be Prominently Featured at Digestive Disease Week(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)...  Renova™ Therapeutics, a biotechnology company developing gene ... 2 diabetes, announced that it has obtained a ... vector developed in the laboratory of Professor ... The company plans to use this vector in ... "Early research has shown promise ...
(Date:12/8/2016)... Oxford Gene Technology (OGT), ... panel range with the launch of the SureSeq myPanel™ NGS ... variants in familial hypercholesterolemia (FH). The panel delivers single nucleotide ... single small panel and allows customisation by ,mix and match, ... for LDLR , P C SK9 ...
(Date:12/8/2016)... ... , ... This CAST literature review and report looks at problems caused by ... economic effects in countries that are major global commodity exporters and importers, which show ... of low level presence (LLP) puts large volumes of trade worth billions of dollars ...
(Date:12/8/2016)... SEOUL, South Korea , Dec. 8, 2016 /PRNewswire/ ... completed a $21 billion KRW (US $18.9M) Series A ... Management, Kolon Investment, G.N. Tech Venture and SNU Bio ... by Eutilex to 30.5 billion KRW (US $27.7M) since ... will help Eutilex to bolster the development and commercialization ...
Breaking Biology Technology:
(Date:11/16/2016)... 2016 Sensory Inc ., a ... for consumer electronics, and VeriTran , a ... industry, today announced a global partnership that will ... authenticate users of mobile banking and mobile payments ... software which requires no specialized biometric scanners, yet ...
(Date:11/14/2016)... , Nov. 14, 2016  Based on ... market, Frost & Sullivan recognizes FST Biometrics ... Award for Visionary Innovation Leadership. FST Biometrics ... biometric identification market by pioneering In Motion ... for instant, seamless, and non-invasive verification. This ...
(Date:6/22/2016)... On Monday, the Department of Homeland Security ... solutions for the Biometric Exit Program. The Request for ... (CBP), explains that CBP intends to add biometrics to ... United States , in order to deter visa ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):